Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cancer

Date Submitted: Oct 9, 2021
Date Accepted: May 18, 2022

The final, peer-reviewed published version of this preprint can be found here:

Timing and Motivations for Alternative Cancer Therapy With Insights From a Crowdfunding Platform: Cross-sectional Mixed Methods Study

Peterson J, Wilson T, Gruhl J, Davis S, Olsen J, Parsons M, Kann B, Fagerlin A, Watt M, Johnson S

Timing and Motivations for Alternative Cancer Therapy With Insights From a Crowdfunding Platform: Cross-sectional Mixed Methods Study

JMIR Cancer 2022;8(2):e34183

DOI: 10.2196/34183

PMID: 35671074

PMCID: 9214612

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Timing and Motivations for Alternative Cancer Therapy: Insights from a Crowdfunding Platform

  • John Peterson; 
  • Trevor Wilson; 
  • Josh Gruhl; 
  • Sydney Davis; 
  • Jaxon Olsen; 
  • Mathew Parsons; 
  • Benjamin Kann; 
  • Angela Fagerlin; 
  • Melissa Watt; 
  • Skyler Johnson

ABSTRACT

Background:

Alternative cancer therapy is associated with increased mortality, but little is known about those who pursue it.

Objective:

We aimed to describe individuals’ motivations for using alternative cancer therapies and determine whether motivations differ based on individuals’ timing of seeking alternative therapies.

Methods:

We used data from 649 campaigns posted on GoFundMe® between 2011 and 2019 for beneficiaries with cancer pursuing alternative therapy. The data were analyzed using a mixed-methods approach. Campaigns were categorized by timing of alternative therapy (either before or after experiencing conventional therapy). Qualitative analysis identified motivational themes. Chi-square tests of independence and Fisher tests, all two-sided, determined significant differences in the presence of motivational themes between groups.

Results:

Campaigns for individuals who used conventional therapy first were significantly more likely to express concerns about efficacy of conventional therapy (63.3% vs. 41.7%, P<.001). Those who started with alternative therapy (compared to those who later switched from conventional to alternative therapy) more often expressed natural and holistic values (49.3% vs. 27.0%, P<.001), an unorthodox understanding of cancer (25.5% vs. 16.4%, P=.004), referenced religious or spiritual beliefs (15.1% vs. 8.9%, P=.01), perceived alternative treatment as efficacious (19.1% vs. 10.2%, P=.001), and distrusted pharmaceutical companies (3.2% vs. 0.5%, P=.04).

Conclusions:

Individuals sought treatments that reflected their values and beliefs, even if scientifically unfounded. Many individuals who reported prior conventional cancer treatment were motivated to pursue alternative treatments because they perceived the conventional treatments to be ineffective.


 Citation

Please cite as:

Peterson J, Wilson T, Gruhl J, Davis S, Olsen J, Parsons M, Kann B, Fagerlin A, Watt M, Johnson S

Timing and Motivations for Alternative Cancer Therapy With Insights From a Crowdfunding Platform: Cross-sectional Mixed Methods Study

JMIR Cancer 2022;8(2):e34183

DOI: 10.2196/34183

PMID: 35671074

PMCID: 9214612

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.